Last reviewed · How we verify
BR1018A
BR1018A is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.
BR1018A is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity. Used for Oncology indication (specific indication not publicly disclosed).
At a glance
| Generic name | BR1018A |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BR1018A is being developed by Boryung Pharmaceutical as an immunooncology agent in Phase 3 clinical trials. The specific molecular mechanism and target remain proprietary and not fully disclosed in public literature, though the company's pipeline suggests focus on checkpoint inhibition or related immunotherapy approaches.
Approved indications
- Oncology indication (specific indication not publicly disclosed)
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C (PHASE3)
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BR1018A CI brief — competitive landscape report
- BR1018A updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI